Chinese BioTech company, Clover Biopharmaceuticals is starting their coronavirus vaccine testing.
Clover is joining five other Chinese medicine companies in the race for the vaccine. Joined by companies GlaxoSmithKline and Dynavax, Phase 1 trials have started. These companies are providing adjuvants that are put into the vaccine and are expected to enhance the immune response. This is important in the current situation as it reduces the amount of antigen required per dose, allowing for more production.
Phases make up vaccine testing. Each phase introduces more volunteers to the vaccine. Phase one of Clover’s trials will consist of about 150 adult and elderly patients, according to Reuters. Other Chinese companies, CanSino Biologics and Sinovac, have already announced positive results from their tests. Clover has initial safety data slated for August.
Phase 2b/3 is in the planning stage. These trials are expected to begin by the end of the year.